XML 166 R150.htm IDEA: XBRL DOCUMENT v3.20.4
Going Conern (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC) (10-K) - USD ($)
3 Months Ended 9 Months Ended 10 Months Ended 12 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Nov. 05, 2018
Dec. 31, 2019
Dec. 31, 2018
Accumulated deficit $ (136,187,000)   $ (136,187,000)     $ (131,457,000) $ (129,394,000)
Net loss (1,481,000) $ (351,000) (4,722,000) $ (754,000)   (2,047,000) (259,000)
Net cash used in operating activities     (3,280,000) 1,761,000   2,744,000 1,365,000
Brooklyn Immunotherapeutics, LLC [Member]              
Cash 3,055,012 $ 6,260,338 3,055,012 6,260,338   5,014,819 6,325,431
Accumulated deficit $ (16,014,329)   (16,014,329)     (10,941,526) (2,004,472)
Net loss     (5,072,803) (6,134,389)   8,937,054  
Net cash used in operating activities     (6,463,285) (8,202,087)   9,800,291 18,436,717
Cash proceeds from sale of members' equity     3,858,750 7,395,750   7,808,250  
Proceeds from investor deposits       437,500  
Proceeds from the collection of subscriptions receivable     $ 275,000 $ 850,000   850,000  
Additional cash for capital call commitments           $ 3,858,750  
Brooklyn Immunotherapeutics, LLC [Member] | Predecessor [Member]              
Cash         $ 250,296    
Net loss         (16,098,602)    
Net cash used in operating activities         (16,285,693)   $ 16,285,693
Cash proceeds from sale of members' equity            
Proceeds from investor deposits            
Proceeds from the collection of subscriptions receivable